FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180502637> ?p ?o ?g. }

• W3180502637 abstract "You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-19 TYPE OF ANDROGEN DEPRIVATION THERAPY AND THE RISK OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PROSTATE CANCER WITH OR WITHOUT PRE-EXISTING CARDIOVASCULAR RISK Alice Dragomir, Nawar Touma, and Armen Aprikian Alice DragomirAlice Dragomir More articles by this author , Nawar ToumaNawar Touma More articles by this author , and Armen AprikianArmen Aprikian More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Controversies exist regarding the risk of cardiovascular events in prostate cancer patients treated with androgen deprivation therapy (ADT). We sought to evaluate the association between gonadotropin-releasing hormone (GnRH) agonists versus GnRH antagonist (Degarelix) and the risk of cardiovascular disease (CVD) in patients with prostate cancer with or without prior CVD. METHODS: Using administrative databases from the province of Quebec in Canada, we identified patients initiating androgen deprivation therapy (ADT) between Jan 2012 and June 2016. Two groups of patients were defined based on the type of ADT received at the 1st prescription: GnRH agonists and Degarelix groups. To be included, patients had to be new users of ADT. The end of follow-up was the date of the first CVD (myocardial infarction (MI), stroke, ischemic heart disease (IHD), arrhythmia and heart failure (HF)), switch of GnRH group, death or Dec 13, 2016. The inverse probability of treatment weighting (IPTW) based on propensity score was used to reduce the effect of potential confounding. IPTW-Cox proportional hazard model for competing risk was used to evaluate the association between the exposure to GnRH agonists or antagonist, and the risk of CVD. RESULTS: This study cohort consists of 10,785 patients: 10,201 initiating GnRH agonists and 584 initiating Degarelix. Mean age was 75 years old, similar between groups. A total of 3,304 (32.4%) and 236 (40.4%) men had CVD in the year prior to ADT initiation, in GnRH agonists and antagonist groups, respectively. A decreased risk of MI, stroke and HF was observed in Degarelix group, yet the Hazard ratios (HR) were not significant (HR: 0.63; 95% confidence interval (CI) 0.37-1.07, HR: 0.76; 95%CI 0.42-1.37 and HR: 0.64; 95%CI 0.41-1.00, respectively). But, an increased risk of arrhythmia was observed (HR:1.46; 95%CI 1.18-1.81) in Degarelix group when compared to the GnRH agonist group. CONCLUSIONS: Degarelix was found to be associated with the risk of developing arrhythmia compared to GnRH agonists in patients with prostate cancer regardless of pre-existing cardiovascular risk. Yet, it might be associated with a decreased risk for other CVDs in this population. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e419-e419 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alice Dragomir More articles by this author Nawar Touma More articles by this author Armen Aprikian More articles by this author Expand All Advertisement Loading ..." @default.
• W3180502637 created "2021-07-19" @default.
• W3180502637 creator A5011409835 @default.
• W3180502637 creator A5013738585 @default.
• W3180502637 creator A5089537082 @default.
• W3180502637 date "2021-09-01" @default.
• W3180502637 modified "2023-09-27" @default.
• W3180502637 title "MP24-19 TYPE OF ANDROGEN DEPRIVATION THERAPY AND THE RISK OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PROSTATE CANCER WITH OR WITHOUT PRE-EXISTING CARDIOVASCULAR RISK" @default.
• W3180502637 doi "https://doi.org/10.1097/ju.0000000000002015.19" @default.
• W3180502637 hasPublicationYear "2021" @default.
• W3180502637 type Work @default.
• W3180502637 sameAs 3180502637 @default.
• W3180502637 citedByCount "0" @default.
• W3180502637 crossrefType "journal-article" @default.
• W3180502637 hasAuthorship W3180502637A5011409835 @default.
• W3180502637 hasAuthorship W3180502637A5013738585 @default.
• W3180502637 hasAuthorship W3180502637A5089537082 @default.
• W3180502637 hasBestOaLocation W31805026371 @default.
• W3180502637 hasConcept C121608353 @default.
• W3180502637 hasConcept C126322002 @default.
• W3180502637 hasConcept C143998085 @default.
• W3180502637 hasConcept C2777899217 @default.
• W3180502637 hasConcept C2778198053 @default.
• W3180502637 hasConcept C2778311097 @default.
• W3180502637 hasConcept C2779134260 @default.
• W3180502637 hasConcept C2780192828 @default.
• W3180502637 hasConcept C71924100 @default.
• W3180502637 hasConceptScore W3180502637C121608353 @default.
• W3180502637 hasConceptScore W3180502637C126322002 @default.
• W3180502637 hasConceptScore W3180502637C143998085 @default.
• W3180502637 hasConceptScore W3180502637C2777899217 @default.
• W3180502637 hasConceptScore W3180502637C2778198053 @default.
• W3180502637 hasConceptScore W3180502637C2778311097 @default.
• W3180502637 hasConceptScore W3180502637C2779134260 @default.
• W3180502637 hasConceptScore W3180502637C2780192828 @default.
• W3180502637 hasConceptScore W3180502637C71924100 @default.
• W3180502637 hasIssue "Supplement 3" @default.
• W3180502637 hasLocation W31805026371 @default.
• W3180502637 hasOpenAccess W3180502637 @default.
• W3180502637 hasPrimaryLocation W31805026371 @default.
• W3180502637 hasRelatedWork W1996941066 @default.
• W3180502637 hasRelatedWork W2046367233 @default.
• W3180502637 hasRelatedWork W2141447267 @default.
• W3180502637 hasRelatedWork W2162051638 @default.
• W3180502637 hasRelatedWork W2244450389 @default.
• W3180502637 hasRelatedWork W2982156914 @default.
• W3180502637 hasRelatedWork W3014214351 @default.
• W3180502637 hasRelatedWork W3197369076 @default.
• W3180502637 hasRelatedWork W4297472852 @default.
• W3180502637 hasRelatedWork W2263670288 @default.
• W3180502637 hasVolume "206" @default.
• W3180502637 isParatext "false" @default.
• W3180502637 isRetracted "false" @default.
• W3180502637 magId "3180502637" @default.
• W3180502637 workType "article" @default.